Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

Roche Holding expects sales and core earnings to keep growing this year after beating analysts' expectations for 2024. The ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

I tell people I feel blessed to not be diagnosed with cancer in the US. Right now pauses on federal funding, including grants ...

After a first eight-minute loading dose, each treatment takes about five minutes to administer and can be carried out at home. In contrast, Herceptin/Perjeta administration needs to be done in a ...

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab ... and is indicated for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

For many women battling breast cancer, or any other type of cancer, the journey is not just about surviving, but also ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.